Compare EHang Holdings Ltd - ADR (EH) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Travere Therapeutics Inc. Common Stock — how do they compare? EHang Holdings Ltd - ADR trades at $3.77 (market cap $289.73M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 16.8× EHang Holdings Ltd - ADR's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 47 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EH | TVTX | |
|---|---|---|
Market Cap | $289.73M | $4.88B |
Volume | 749,255 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $18.94 | $67.52 |
52-Week Low | $3.78 | $26.79 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $241.33M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $3.78, down 4.79% on the day, reflecting a bearish technical trend. The company reported revenue of $418 million for 2025 but posted a net loss of $276 million, with negative profit margins and ROE. Recent news includes a law firm investigation into investor claims and expansion of its Global Fast Track Program to Vietnam. Cash flow from operations turned positive in 2024 at $158 million, but investing activities remain heavily negative due to capital expenditures.
The outlook is highly speculative, with significant execution and regulatory risks. Investment opportunity hinges on successful commercialization of eVTOL technology, but persistent losses and bearish analyst sentiment suggest caution. Key risks include ongoing legal scrutiny, intense competition, and reliance on future regulatory approvals for growth.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
